Clinical Trial Update: Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating AVP-923 (dextromethorphan/quinidine) for agitation in Alzheimer's disease completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Agitation
• Alzheimer Disease

Drugs mentioned

• AVP-923

Snippet

Sponsor: Avanir Pharmaceuticals | Conditions: Agitation, Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2021-11-26